Business Context and Reporting Period
This Form 6-K filing by NeuroSense Therapeutics Ltd. covers the month of July 2026. The report details an amendment to the Company's existing Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC.
Key Financial Metrics
The filing does not provide a full set of financial statements, revenue, profit, or cash flow data. However, it discloses the following capital raising metrics as of July 31, 2026:
- Total Shares Sold: 6,762,825 ordinary shares under the Sales Agreement.
- Net Proceeds: Approximately $6.7 million.
- Remaining Capacity: The amended agreement allows for the offer and sale of ordinary shares with an aggregate offering price of up to $3,789,822.
Material Changes
The primary material change is the execution of Amendment No. 1 to the Sales Agreement dated August 16, 2024. This amendment updates the agreement to reference a new registration statement on Form F-3 (File No. 333-293060), which was declared effective on July 31, 2026, replacing references to the prior registration statement (File No. 333-269306).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors beyond standard legal disclaimers. It notes that the report does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful without registration. The Sales Agreement remains in full force and effect except as amended.
Investor Verification Checklist
- Verify the full text of Amendment No. 1 filed as Exhibit 10.1 to this Form 6-K.
- Confirm the details of the new Form F-3 registration statement (File No. 333-293060) and its effective date.
- Review the original Sales Agreement filed as Exhibit 10.1 to the August 16, 2024 Form 6-K to understand the complete terms of the Capital on Demand program.
- Monitor future filings for actual sales activity under the remaining $3.79 million capacity.